

**VERTEX PHARMACEUTICALS INCORPORATED**

130 Waverly Street
Cambridge, MA 02139-4242
Tel. 617.444.6100 Fax 617.444.6680
www.vrtx.com

FAX**RECEIVED
CENTRAL FAX CENTER****JUN 23 2005**


To	Commisssloner for Patents
Company	USPTO
FAX	(703) 872-9306
From	Lisa A. Dixon
Date	June 23, 2005
Subject	Application No. 10/743,563 Attorney Docket No. VPI/02-131 US
Total Pages	8

Message or Comment

In response to the Restriction Requirement relating to the above-identified application, please find attached a Transmittal letter in duplicate (2 pages) and Reply (3 pages).

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this correspondence, and any documents referred to as attached hereto, is/are being transmitted to the United States Patent and Trademark Office, Facsimile Number: (703) 872-9306 on June 23, 2005.



Lisa A. Dixon

If any problems occur with this fax transmittal, please call (617) 444-6396 immediately.

FAX Number (617) 444-6483 Legal Department

CONFIDENTIALITY NOTICE

The information and the documents transmitted by this telecopy are privileged and contain confidential information intended only for the person (s) names above. Any other distribution, copying or disclosure is strictly prohibited. If you have received this telecopy in error, please notify us immediately by telephone and return the original to us without making a copy.

RECEIVED
CENTRAL FAX CENTER

JUN 23 2005

For Other Than A Small Entity

VPI/02-131 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Zinna Northington Davis
Group : 1625
Applicants : Charrier et al.
Serial No. : 10/743,563
Confirmation No. : 5056
Filed : December 22, 2003
For : CASPASE INHIBITORS AND USES THEREOF

Cambridge, Massachusetts
June 23, 2005

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER


Sir:

Transmitted herewith: ☒ a Response to Office Action/Restriction Requirement;
☐ a Petition for One Month Extension of Time; ☐ a substitute Specification; ☐ a Declaration;
☐ a Supplemental Declaration; ☐ a Power of Attorney; ☐ an Associate Power of Attorney; ☐
formal drawings; to be filed in the above-identified patent application.

VPI/02-131 US

- [X] The Director is hereby authorized to charge payment of any additional filing fees required under 37 C.F.R. § 1.16, in connection with the paper(s) transmitted herewith, or credit any overpayment of same, to deposit Account No. 50-0725. A duplicate copy of this transmittal letter is transmitted herewith.
- [] Please charge \$___ to Deposit Account No. 50-0725 in payment of the filing fee. A duplicate copy of this transmittal letter is transmitted herewith.

Dated: June 23, 2005



Lisa A. Dixon (Reg. No. 40,995)
Agent for Applicants
VERTEX PHARMACEUTICALS
INCORPORATED
130 Waverly Street
Cambridge, MA 02139
Tel: (617) 444-6396
Fax: (617) 444-6483
Customer No.: 27916**CERTIFICATE OF FACSIMILE TRANSMISSION**

I hereby certify that this correspondence, and any documents referred to as attached hereto, is/are being transmitted to the United States Patent and Trademark Office, Facsimile Number: (703) 872-9306 on June 23, 2005.



Lisa A. Dixon

RECEIVED
CENTRAL FAX CENTER

JUN 23 2005

For Other Than A Small Entity

VPL/02-131 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Zinna Northington Davis
Group : 1625
Applicants : Charrier et al.
Serial No. : 10/743,563
Confirmation No. : 5056
Filed : December 22, 2003
For : CASPASE INHIBITORS AND USES THEREOF

Cambridge, Massachusetts
June 23, 2005

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER


Sir:

Transmitted herewith: ☒ a Response to Office Action/Restriction Requirement;
☐ a Petition for One Month Extension of Time; ☐ a substitute Specification; ☐ a Declaration;
☐ a Supplemental Declaration; ☐ a Power of Attorney; ☐ an Associate Power of Attorney; ☐
formal drawings; to be filed in the above-identified patent application.

VPI/02-131 US

- ☒ The Director is hereby authorized to charge payment of any additional filing fees required under 37 C.F.R. § 1.16, in connection with the paper(s) transmitted herewith, or credit any overpayment of same, to deposit Account No. 50-0725. A duplicate copy of this transmittal letter is transmitted herewith.
- ☐ Please charge \$___ to Deposit Account No. 50-0725 in payment of the filing fee. A duplicate copy of this transmittal letter is transmitted herewith.

Dated: June 23, 2005



Lisa A. Dixon (Reg. No. 40,995)
Agent for Applicants
VERTEX PHARMACEUTICALS
INCORPORATED
130 Waverly Street
Cambridge, MA 02139
Tel: (617) 444-6396
Fax: (617) 444-6483
Customer No.: 27916**CERTIFICATE OF FACSIMILE TRANSMISSION**

I hereby certify that this correspondence, and any documents referred to as attached hereto, is/are being transmitted to the United States Patent and Trademark Office, Facsimile Number: (703) 872-9306 on June 23, 2005.



Lisa A. Dixon

RECEIVED
CENTRAL FAX CENTER

006/008

JUN 23 2005

Attorney Docket No. VPI/02-131

Examiner : Zinna Northington Davis
Group : 1625
Applicants : Charrier et al.
Serial No. : 10/743,563
Confirmation No. : 5056
Filed : December 22, 2003
For : CASPASE INHIBITORS AND USES THEREOF

Cambridge, Massachusetts
June 23, 2005

REPLY TO RESTRICTION REQUIREMENT

Sir:

This is in reply to the May 23, 2005 Restriction Requirement in the above-identified application. The time for reply to this Office Action is, therefore, up to and including June 23, 2005. Accordingly, this reply is timely filed.

Remarks begin at page 2 of this Reply.